美国众议院于2024年9月9日通过了《BIOSECURE法》,禁止联邦机构从WuXi AppTec和BGI等中国公司购买生物技术。 The U.S. House passed the BIOSECURE Act on Sept 9, 2024, banning federal agencies from purchasing biotech from Chinese firms like WuXi AppTec and BGI.

美国众议院于2024年9月9日通过了BIOSECURE法,其目的是阻止联邦机构向外国对手购买生物技术,特别是向WuXi AppTec和BGI等中国公司购买生物技术。 The BIOSECURE Act, passed by the U.S. House on September 9, 2024, aims to block federal agencies from purchasing biotechnology from foreign adversaries, particularly Chinese firms like WuXi AppTec and BGI. 它禁止与这些公司签订合同,并禁止在2032年1月1日前逐步取消现有协定。 It prohibits contracts with these companies and mandates phasing out existing agreements by January 1, 2032. 在两党支持下,该法案不久将提交参议院,影响中美生物技术关系,并可能增加成本和延误。 With bipartisan support, the bill may soon advance to the Senate, impacting U.S.-China biotech relations and potentially increasing costs and delays.